Piperidinyl-Methyl Purineamines for Selective NSD2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective inhibitors of NSD2, a nuclear receptor-binding SET domain protein associated with various human cancers, as its overexpression is linked to aggressive tumor behavior and poor prognosis.
Innovation Solution
Development of novel compounds, including those of Formula (I) and their enantiomers or pharmaceutically acceptable salts, that inhibit NSD2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSD2 inhibitors are developed to treat cancers, then cancer treatment effectiveness is improved, but selectivity and off-target effects remain challenges
Solution Approach 1:
The patent modifies molecular parameters of NSD2 inhibitors by incorporating specific heterocyclic rings (pyrimidine, pyridine, triazole) and functional groups (carboxylic acid, ester, amide) to optimize binding affinity and selectivity. These parameter changes enable effective NSD2 inhibition while reducing off-target effects through precise molecular structure optimization.
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional moieties (heterocyclic cores with various side chains and terminal groups) to achieve both high efficacy against NSD2 and improved selectivity. The composite nature of these molecules allows simultaneous optimization of binding strength and specificity.
2Productivity
If NSD2 activity is inhibited to reduce tumor growth, then cancer progression is slowed, but resistance development may occur
Solution Approach 1:
The patent employs multiple distinct molecular series (Formula I with various R1-R8 substituents) that can target different aspects of NSD2 function or bind to slightly different conformational states. This segmentation of the inhibitor portfolio increases the likelihood of overcoming resistance mechanisms by having diverse molecules with different binding modes and cellular effects.
Solution Approach 2:
The invention incorporates flexible molecular structures with variable side chains and rotatable bonds that can adapt to different NSD2 conformations and mutate-prone regions. This dynamic adaptability allows the inhibitors to maintain binding affinity even when NSD2 undergoes minor structural changes or mutations, thereby reducing resistance development.
3Object-affected harmful factors
If selective NSD2 inhibitors are designed to improve therapy specificity, then off-target effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies local quality modifications by introducing specific functional groups and heterocyclic motifs at particular positions in the molecular structure. Each substituent (R1-R8) is carefully positioned to provide specific binding interactions with NSD2 while maintaining overall molecular manageability. This localized optimization achieves selectivity without requiring complete redesign of the entire molecular architecture.
Data Source
AI summary
The present invention provides a compound of Formula (I):or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).